Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations
Contact your GP for an initial assessment including BMI calculation, comorbidity review, and discussion of previous weight loss attempts
Every time you puncture the rubber stopper with a syringe, you introduce a tiny amount of air and a potential for contamination
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry
Existing studies, while showing similar trends in weight reduction and HbA1c improvement for both formulations, often reveal subtle numerical differences
Under water stress, electrolyte leakage is considered to be a symbol of damage and descent 63
